Novavax

GoodRx highlights seven potential FDA drug approvals in 2025, including Ozempic for chronic kidney disease, Leqembi for Alzheimer's, Suzetrigine as a novel painkiller, Gepotidacin for UTIs, Cardamyst for PSVT, and Novavax's COVID-19 vaccine for full approval.

Novavax Inc's shares rose 13.5% to $11.09 amid a CDC report on increased U.S. respiratory illnesses, boosting interest in vaccine developers. The company's non-mRNA COVID-19 vaccine, Nuvaxovid, offers an alternative to mRNA vaccines. Novavax is also developing combination vaccines for COVID-19 and influenza, highlighting its role in combating respiratory viruses.

26,742 individuals recently engaged with the daily Crossword, challenging others to solve it faster.

Vaccine makers' stocks surged after the US reported its first bird flu death, with Moderna, Novavax, and CureVac seeing significant gains. Companies are developing mRNA vaccines for the virus. The CDC reported the death involved the H5 strain, with 66 US cases since last year. Risk to the public remains low, with no human transmission recorded.

Six international stocks stand out, with Eli Lilly highlighted for its weight-loss drugs Mounjaro and Zepbound, showing strong sales growth. Pharma stocks face uncertainty under Trump's potential presidency. BlackRock and CrowdStrike are noted for their AI and cybersecurity investments, respectively. Access Holdings and Nu Holdings are praised for their aggressive expansion and financial performance in Africa and Latin America.

Five years ago, a novel virus emerged in Wuhan, China, leading to a global pandemic. Its origin remains uncertain, with theories suggesting animal transmission or a lab leak. Over 20 million deaths are estimated worldwide. Vaccines, developed rapidly, have saved millions but require updates for evolving variants like omicron. Long COVID affects millions with persistent symptoms, its cause and treatment still unclear.

Metformin lowers COVID-19 viral loads; long COVID affects brain function for years. HLA gene variant linked to asymptomatic infections. COVID symptoms include diarrhea, nausea. Free at-home tests ended; oral antivirals available until 2024. Vaccination may delay menstrual cycle. Omicron and its subvariants dominate, with KP.2 and JN.1 being notable. Long COVID symptoms include fatigue, brain fog. Vaccines' myocarditis risk is low. Pregnant vaccinated women have higher COVID risk. No elevated stroke/heart attack rates post-vaccination. J&J vaccine limited due to blood clot risk.

A study found RSV vaccine responses weaker in immunocompromised older adults, with 61% seroconverting. Adjuvanted vaccines showed better neutralization, suggesting potential for enhanced doses in this group.

DelveInsight's 2024 COVID-19 Pipeline Insight report details over 180 companies and 200+ pipeline drugs, covering clinical and nonclinical stages, therapeutic assessments, and inactive products. Highlights include Novavax's JN.1 subvariant vaccine and Gilead Sciences' obeldesivir trial. Promising therapies like DAS181 and Sarconeos are in advanced clinical trials.

The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.